Losing weight has ‘hidden benefits' and clears out damaged cells
They examined hundreds of thousands of cells to produce the first very detailed analysis of the changes weight loss causes in human fat tissue.
Numerous benefits of losing weight were identified, including the clearing out of damaged, ageing cells, and increased metabolism of harmful fats.
The findings could, in future, help in the development of therapies for diseases such as type 2 diabetes, the team said.
The study, published in the journal Nature, compared samples of fat tissue from people with a healthy weight with samples from people with severe obesity (BMI over 35) undergoing bariatric weight loss surgery.
The weight loss group had fat samples taken during surgery and more than five months afterwards, at which point they had lost an average of 25kg.
Researchers from the Medical Research Council (MRC) Laboratory of Medical Sciences in London, and from Imperial College London, analysed gene expression in more than 170,000 cells that made up the fat tissue samples, from 70 people.
They discovered that weight loss triggers the breakdown and recycling of fats called lipids.
This recycling process could be responsible for burning energy and reversing the harmful build-up of lipids in other organs like the liver and pancreas, they said.
Further research is now needed to work out if lipid recycling is linked to the positive effects of weight loss on health, such as remission of type 2 diabetes.
Scientists also found that the weight loss cleared out senescent cells, which are ageing and damaged cells that accumulate in all tissues.
These cells no longer function properly and release signals that lead to tissue inflammation and scarring.
Dr William Scott, who led the study, said: 'We've known for a long time that weight loss is one of the best ways to treat the complications of obesity, such as diabetes, but we haven't fully understood why.
'This study provides a detailed map of what may actually be driving some of these health benefits at a tissue and cellular level.
'Fat tissues have many under-appreciated health impacts, including on blood sugar levels, body temperature, hormones that control appetite, and even reproductive health.
'We hope that new information from studies like ours will start to pave the way for developing better treatments for diabetes and other health problems caused by excess body fat.'
Researchers found that weight loss did not, however, improve the effects of obesity on some aspects of the immune system.
Inflammatory immune cells, for example, did not fully recover even after weight loss.
Experts said this type of inflammatory cell memory could be harmful in the long term if people regain weight.
The study was funded by the Medical Research Council, Diabetes UK and Wellcome.
Dr Faye Riley, research communications lead at Diabetes UK, said: 'For some people, losing weight can put their type 2 diabetes into remission.
'But weight loss is challenging, and current approaches don't work for everyone.
'This research offers a rare window into the changes that occur in fat tissue during weight loss that may be key to improving health and putting type 2 diabetes into remission.
'By deepening our understanding of these processes, the study could open the door to innovative therapies that mimic the effects of weight loss, potentially helping people with type 2 diabetes to manage their condition or go into remission.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
UN says if US funding for HIV programs is not replaced, millions more will die by 2029
LONDON — Years of American-led investment into AIDS programs has reduced the number of people killed by the disease to the lowest levels seen in more than three decades, and provided life-saving medicines for some of the world's most vulnerable. But in the last six months, the sudden withdrawal of U.S. money has caused a 'systemic shock,' U.N. officials warned, adding that if the funding isn't replaced, it could lead to more than 4 million AIDS-related deaths and 6 million more HIV infections by 2029.
Yahoo
an hour ago
- Yahoo
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of positive results from its Phase 2a, OVX836-004, study in the journal Vaccines. The study evaluated the safety and immunogenicity of co-administering OVX836, Osivax' broad-spectrum influenza vaccine candidate, with the hemagglutinin antigen (HA)-based inactivated influenza vaccine Fluarix® Tetra. The full article 'Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix® Tetra, a Seasonal Hemagglutinin-Based Vaccine' is now available online. In the OVX836-004 study (NCT05284799), 180 healthy adults aged 18 to 55 years were randomized to each receive two concomitant intramuscular injections of Fluarix® Tetra and placebo, Fluarix® Tetra and OVX836 (480 µg), or OVX836 and placebo, both administered into the deltoid muscle of the non-dominant arm. Key findings include: Favorable safety and tolerability profile of OVX836 when administered alone or in combination with Fluarix® Tetra; no severe or unsolicited adverse events were reported Comparable local and systemic reactions across all treatment groups Strong HA-specific antibody responses were observed in all groups immunized with Fluarix® Tetra, whether co-administered with OVX836 or as a stand-alone, with similar HAI titers across all four influenza strains Robust NP-specific immune responses, both humoral and cell-mediated, were measured in all groups receiving OVX836, whether co-administered with Fluarix® Tetra or as a stand-alone 'The favorable safety profile and strong immune response observed in this study provide encouraging evidence that OVX836 can be co-administered with a standard seasonal influenza vaccine,' commented Dr. Nicola Groth, MD, CMO of Osivax. 'These findings support the potential of OVX836 to lead to higher efficacy due to synergistic effects of the immune responses when combined with standard seasonal flu vaccine and to further reinforce the versatility of our vaccine candidate, marking an important milestone in our efforts to broaden protection against influenza in years of strain mismatches.' 'The results underscore OVX836's strong potential as a valuable component of combination approaches with seasonal vaccines,' added Alexandre Le Vert, CEO and Co-Founder of Osivax. 'By inducing strong and complementary immune responses, our approach positions us to meaningfully advance influenza prevention on a broader scale. The data collected will support the continued development of OVX836 as we focus on a single-injection formulation that streamlines vaccination delivery and maximizes public health impact.' About OVX836 OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, the NP is much less likely to mutate, providing a broader and more universal immune response. Osivax' oligoDOMTM technology enables the design and production of a recombinant version of the NP, which self-assembles into a nanoparticle, thus triggering powerful T- and B-cell immune responses. OVX836 has been tested in 7 clinical trials with 1,400 participants so far, and has shown promising safety, immunogenicity, and efficacy read-outs. About OVX836-004OVX836-004 is a randomized, double-blind, reference-controlled, single-center Phase 2a clinical trial run in Australia (NCT05284799), to assess the co-administration of NP-based flu vaccine OVX836 at 480μg with a conventional seasonal, HA-based quadrivalent inactivated influenza virus vaccine (QIV), the current standard of care in the flu vaccine market. The clinical study is evaluating the safety and level of immune response generated by each vaccine individually and when co-administered to confirm the absence of immune interference. About Osivax Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOMTM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum influenza vaccine candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,400 volunteers tested and encouraging efficacy proof of concept data. Osivax' ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide. For further information: ContactAlexandre LE VERT, CEOcontact@ (0)9 70 30 13 80 For Media InquiriesTrophic CommunicationsDesmond James or Anja Heuerosivax@ +49 (0) 151 678 59086 or +49 (0) 151 106 199 05Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
UN says if US funding for HIV programs is not replaced, millions more will die by 2029
LONDON (AP) — Years of American-led investment into AIDS programs has reduced the number of people killed by the disease to the lowest levels seen in more than three decades, and provided life-saving medicines for some of the world's most vulnerable. But in the last six months, the sudden withdrawal of U.S. money has caused a 'systemic shock,' U.N. officials warned, adding that if the funding isn't replaced, it could lead to more than 4 million AIDS-related deaths and 6 million more HIV infections by 2029. 'The current wave of funding losses has already destabilized supply chains, led to the closure of health facilities, left thousands of health clinics without staff, set back prevention programs, disrupted HIV testing efforts and forced many community organizations to reduce or halt their HIV activities,' UNAIDS said in a report released Thursday. UNAIDS also said that it feared other major donors might also scale back their support, reversing decades of progress against AIDS worldwide — and that the strong multilateral cooperation is in jeopardy because of wars, geopolitical shifts and climate change. The $4 billion that the United States pledged for the global HIV response for 2025 disappeared virtually overnight in January when U.S. President Donald Trump ordered that all foreign aid be suspended and later moved to shutter the U.S. AID agency. Andrew Hill, an HIV expert at the University of Liverpool who is not connected to the United Nations, said that while Trump is entitled to spend U.S. money as he sees fit, 'any responsible government would have given advance warning so countries could plan,' instead of stranding patients in Africa when clinics were closed overnight. The U.S. President's Emergency Plan for AIDS Relief, or PEPFAR, was launched in 2003 by U.S. President George W. Bush, the biggest-ever commitment by any country focused on a single disease. UNAIDS called the program a 'lifeline' for countries with high HIV rates, and said that it supported testing for 84.1 million people, treatment for 20.6 million, among other initiatives. According to data from Nigeria, PEPFAR also funded 99.9% of the country's budget for medicines taken to prevent HIV. In 2024, there were about 630,000 AIDS-related deaths worldwide, per a UNAIDS estimate — the figure has remained about the same since 2022 after peaking at about 2 million deaths in 2004. Even before the U.S. funding cuts, progress against curbing HIV was uneven. UNAIDS said that half of all new infections are in sub-Saharan Africa and that more than 50% of all people who need treatment but aren't getting it are in Africa and Asia. Tom Ellman, of the charity Doctors Without Borders, said that while some poorer countries were now moving to fund more of their own HIV programs, it would be impossible to fill the gap left by the U.S. 'There's nothing we can do that will protect these countries from the sudden, vicious withdrawal of support from the U.S.,' said Ellman, director of Doctors Without Borders' South Africa Medical Unit. 'Within months of losing treatment, people will start to get very sick and we risk seeing a massive rise in infection and death.' Experts also fear another loss: data. The U.S. paid for most HIV surveillance in African countries, including hospital, patient and electronic records, all of which has now abruptly ceased, according to Dr. Chris Beyrer, director of the Global Health Institute at Duke University. 'Without reliable data about how HIV is spreading, it will be incredibly hard to stop it,' he said. The uncertainty comes as a twice-yearly injectable could end HIV, as studies published last year showed that the drug from pharmaceutical maker Gilead was 100% effective in preventing the virus. Last month, the U.S. Food and Drug Administration approved the drug, called Sunleca — a move that should have been a 'threshold moment' for stopping the AIDS epidemic, said Peter Maybarduk of the advocacy group Public Citizen. But activists like Maybarduk said Gilead's pricing will put it out of reach of many countries that need it. Gilead has agreed to sell generic versions of the drug in 120 poor countries with high HIV rates but has excluded nearly all of Latin America, where rates are far lower but increasing. 'We could be ending AIDS," Maybarduk said. "Instead, the U.S. is abandoning the fight.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at Maria Cheng, The Associated Press
